argenx SE (NASDAQ:ARGX) Shares Purchased by Voya Investment Management LLC

Voya Investment Management LLC grew its stake in shares of argenx SE (NASDAQ:ARGX - Free Report) by 47.8% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 14,170 shares of the company's stock after buying an additional 4,585 shares during the quarter. Voya Investment Management LLC's holdings in argenx were worth $8,715,000 at the end of the most recent quarter.

A number of other large investors have also bought and sold shares of the stock. Syon Capital LLC increased its stake in shares of argenx by 4.3% in the 4th quarter. Syon Capital LLC now owns 897 shares of the company's stock worth $552,000 after acquiring an additional 37 shares in the last quarter. MGO One Seven LLC purchased a new position in shares of argenx during the fourth quarter valued at approximately $323,000. Pinebridge Investments L.P. grew its holdings in shares of argenx by 16.1% in the fourth quarter. Pinebridge Investments L.P. now owns 56,925 shares of the company's stock worth $35,009,000 after acquiring an additional 7,909 shares during the period. Diadema Partners LP bought a new position in shares of argenx in the 4th quarter worth approximately $422,000. Finally, Stifel Financial Corp increased its stake in shares of argenx by 6.8% in the 4th quarter. Stifel Financial Corp now owns 9,433 shares of the company's stock worth $5,801,000 after purchasing an additional 601 shares in the last quarter. 60.32% of the stock is owned by hedge funds and other institutional investors.

argenx Price Performance

NASDAQ ARGX traded up $9.77 on Friday, hitting $649.67. The company had a trading volume of 318,117 shares, compared to its average volume of 309,140. The company's fifty day moving average price is $598.32 and its 200-day moving average price is $611.37. The company has a market capitalization of $39.67 billion, a PE ratio of -738.26 and a beta of 0.57. argenx SE has a 12-month low of $352.77 and a 12-month high of $678.21.

argenx (NASDAQ:ARGX - Get Free Report) last posted its quarterly earnings data on Thursday, February 27th. The company reported $1.58 EPS for the quarter, beating the consensus estimate of $0.98 by $0.60. argenx had a negative return on equity of 1.45% and a negative net margin of 2.11%. The firm had revenue of $761.22 million during the quarter, compared to the consensus estimate of $678.52 million. On average, sell-side analysts anticipate that argenx SE will post 3.13 EPS for the current year.

Analysts Set New Price Targets

Several equities analysts have weighed in on the stock. JMP Securities lifted their price target on shares of argenx from $606.00 to $696.00 and gave the company a "market outperform" rating in a report on Tuesday, January 14th. Citigroup upped their price target on shares of argenx from $681.00 to $796.00 and gave the company a "buy" rating in a research note on Thursday, April 17th. Truist Financial reaffirmed a "buy" rating and set a $700.00 price objective (up from $660.00) on shares of argenx in a research note on Tuesday, January 14th. Robert W. Baird raised their price target on argenx from $650.00 to $680.00 and gave the stock a "neutral" rating in a research note on Tuesday, March 4th. Finally, Sanford C. Bernstein raised shares of argenx from a "market perform" rating to an "outperform" rating in a research report on Monday, March 17th. Three research analysts have rated the stock with a hold rating, nineteen have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $699.28.

argenx Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.